Exemestane is a steroidal aromatase inhibitor that irreversibly binds to the enzyme, unlike the reversible binding seen by the nonsteroidal inhibitors anastrozole and letrozole. It has received approval for the treatment of postmenopausal women with advanced breast cancer that has progressed after tamoxifen therapy. It is swiftly absorbed after oral administration and substantially metabolized by CYP3A4. It is often well tolerated, with hot flushes, nausea, and exhaustion being observed as side effects.
The proliferation of breast cancer cells is reliant on estrogen. Aromatase is an enzyme that catalyzes the conversion of androgens to estrogens in both premenopausal and postmenopausal women. In premenopausal women, the ovary is the principal source of estrogen (estradiol). The principal circulating estrogens in postmenopausal women are synthesized by the conversion of adrenal and ovarian androgens (androstenedione and testosterone) into estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Exemestane interacts with aromatase, converting into reactive intermediates that covalently and irreversibly bind to the enzyme, resulting in its inactivation and subsequent destruction by the proteasome; therefore, this inhibition is nicknamed "suicide inhibition." Aromatase degradation transpires in a manner that is reliant on both time and dosage. Exemestane exhibits rapid oral absorption, with effects detectable 2 hours post-administration. Following absorption, about 90% of the chemical associates with plasma proteins, including albumin and α1-acid glycoprotein, reaching peak plasma concentrations within 2 hours post-administration of a single 25 mg dosage. Clinical investigations have determined that a daily oral dosage of 25 mg of exemestane is the lowest effective amount required to achieve optimal estrogen suppression. This single dosage decreases estrogen levels, including estradiol and estrone-sulfate, by 85–95% within 2–3 days, with effects potentially lasting up to 5 days. Furthermore, it causes a sustained reduction in plasma and urine estrogen levels. Moreover, exemestane is widely distributed in tissues and primarily eliminated through urine and feces, with a mean terminal elimination half-life of 24 hours. Nonetheless, this may differ among patients, maybe because to the varied activity of the metabolizing CYP enzymes. Recent advancements in the oral administration of exemestane are being realized through the manufacture of nanoparticles encapsulating the chemical.
An innovative and pragmatic synthetic method, commencing from commercially accessible dehydrotestosterone, revealed an atypical and unprecedented Mannich reaction on a cross-conjugated dienone moiety by facilitating the direct incorporation of the methylene group at the 6-position of a 3-oxo-1,4-diene steroid, executed with paraformaldehyde and dimethylamine in iso-amyl alcohol (i-AmOH) at 130 °C. The hydroxyl group at C-17 of ring D in the beginning steroid must be present to prevent a competitive Mannich reaction from preferentially happening at C-16, should the 17-oxo analogue serve as the synthetic precursor. The 6-methylene intermediate (11), isolated from the aforementioned reaction mixture with a yield of 35%, produced exemestane with an overall yield of 28% following the crystallization of the solid residue from the Jones oxidation process to introduce the 17-keto group.
A feasible alternative synthetic pathway for exemestane was established following an exceptionally effective 6-methylenation of the more affordable and accessible androstenedione, utilizing exclusive knowledge from the industrial synthesis of Farmitalia's medroxyprogesterone acetate. Androstenedione was initially reacted with triethylorthoformate in a tetrahydrofuran (THF)–ethanol mixture at 40 °C, utilizing para-toluenesulfonic acid (p-TsOH) as a catalyst. The resultant ethyl 3,5-dienolether, without isolation, underwent a Mannich reaction with N-methylaniline and aqueous formaldehyde. The adduct intermediate was degraded using concentrated HCl, yielding the 6-methylene intermediate 9 in 73% yield following simple precipitation. The insertion of a double bond at the 1,2-position of the 3-oxo steroid framework can be efficiently achieved by bromination followed by dehydrobromination. In this instance, the bromination of 9 with bromine in THF–AcOH at 0 °C, with a catalytic quantity of HBr, yielded the anticipated tribromide (12) in 84% yield and almost pure form upon precipitation. Partial debromination using sodium iodide in refluxing acetone yielded the crude 2-bromointermediate, which underwent dehydrohalogenation with LiCl and LiCO3 in N,N-dimethylformamide (DMF) at 120 °C to produce exemestane, precipitated with water, in a 47% yield based on androstenedione.
In postmenopausal women with advanced breast cancer, the newer generation of nonsteroidal aromatase inhibitors (AIs) such as letrozole and anastrozole have demonstrated better efficacy when compared to tamoxifen as first-line therapies and to megestrol acetate as second-line therapy. Results from an open-label Phase II study indicated that, in terms of objective response and clinical benefit, exemestane was numerically better than tamoxifen. It is becoming more important to evaluate the pharmacologic profiles and tolerability of these medicines because they may be used in adjuvant settings for up to five years. Anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) all had plasma half-lives of 41-48 hours, 2-4 days, and 27 hours, respectively, at dosages used in clinical trials. Letrozole required 60 days to reach steady-state plasma levels, but anastrozole and exemestane required 7 days. Exemestane is the only one known to cause androgenic adverse effects. Treatment with anastrozole showed no effect on plasma lipid levels, although letrozole and exemestane both had negative effects. When looking at the absence of influence on adrenosteroidogenesis in indirect comparisons, anastrozole exhibited the greatest degree of selectivity compared to exemestane and letrozole.
The intent-to-treat analysis comprised 128 patients (64 on anastrozole and 64 using exemestane) out of 130 total patients. The statistical power of the trial was limited since the study was closed before the goal enrollment (N = 200) was met due to accrual delays. In both groups, the objective response rate at visceral locations was around 15%. Among patients treated with anastrozole, 32% saw clinical benefit in visceral locations, whereas 38% benefited from exemestane. The anastrozole group had a median survival of 33.3 months, while the exemestane group had a median survival of 30.5 months. The toxicities were comparable to those previously documented; however, anastrozole had a higher frequency of treatment-related adverse events (41% vs. 31%). Patients with visceral metastases and postmenopausal breast cancer tolerated both therapies well. For every outcome, the two therapy groups were equally effective. Patients who have gone through menopause and have hormone receptor-positive metastases to organs from their breast cancer may be candidates for aromatase inhibitors.
Two of the most important cancer medications utilized for endocrine therapy of ER-positive breast cancer during the disease's progression are letrozole, an aromatase inhibitor, and exemestane, an aromatase inactivator. There were 79 patients with complete sets of blood samples available, including 40 patients starting with letrozole (cohort 1) and 39 patients starting with exemestane (cohort 2). Cohort 1 had an average serum estradiol level of 46.4 pmol/L and an estrone level of 174 pmol/L. Letrozole treatment reduced blood E1 and E2 levels to an average of 0.2 pmol/L and 0.4 pmol/L, respectively (P < 0.001). The mean blood levels of
